Driving performance of stable outpatients with depression undergoing real‐world treatment
- 27 February 2018
- journal article
- research article
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 72 (6) , 399-408
Abstract
Aim: Although the effects of psychotropics on driving ability have received much attention, little research is available on driving performance of stable outpatients with depression undergoing real‐world treatment. This observational study investigated driving performance, cognitive functions, and depressive symptomatology of partly remitted outpatients with depression under daily‐practice psychopharmacologic treatment.Methods: Seventy stable outpatients with depression and 67 healthy volunteers were enrolled. Patients’ prescriptions were not controlled in order to capture the real‐world treatment environment. Participants underwent three driving tasks – road‐tracking, car‐following, and harsh‐braking – using a driving simulator, and three cognitive tasks – Continuous Performance Test, Wisconsin Card Sorting Test, and Trail‐Making Test. The Symptom Assessment Scale – Structured Interview Guide for the Hamilton Depression Rating Scale, Beck Depression Inventory‐II, Social Adaptation Self‐Evaluation Scale, and Stanford Sleepiness Scale were also completed.Results: Although many patients received various pharmacologic treatments, there were no significant differences in the three driving tasks between outpatients with depression and healthy controls. Difficulty of maintaining set in the Wisconsin Card Sorting Test was significantly increased in patients with depression. Results on the Social Adaptation Self‐Evaluation Scale were significantly associated with road‐tracking and car‐following performance, in contrast to results on the Hamilton Depression Rating Scale and the Beck Depression Inventory‐II.Conclusion: We conclude that partly remitted depressive patients under steady‐state pharmacologic treatment do not differ from healthy controls with respect to driving performance, which seems to be more affected by psychosocial functioning than by pharmacologic agents. This, however, should be investigated systematically in an off/on study.Keywords
Funding Information
- Grant-in-Aid for Young Scientists (JP25861000)
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- ZENKYOREN
- Research on Regulatory Science of Pharmaceuticals and Medical Devices from Japan Agency for Medical Research and Development, AMED
- General Insurance Association of Japan
- Grant-in-Aid for “Center of Innovation for Personalized and Diverse Society” carried out under the Center of Innovation Program by the Japan Science and Technology Agency
- Grant-in-Aid for the Comprehensive Research on Disability Health and Welfare, the Ministry of Health, Labour and Welfare of Japan
- NEXCO Group Companies’ Support Fund to Disaster Prevention Measures on Expressways
- Center of Innovation Program by the Japan Science and Technology Agency
This publication has 49 references indexed in Scilit:
- COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONSDepression and Anxiety, 2013
- The impact of probable anxiety and mood disorder on self-reported collisions: A population studyJournal of Affective Disorders, 2013
- Antidepressant Use and Cognitive Functioning in Older Medical Patients With Major or Minor DepressionJournal of Clinical Psychopharmacology, 2011
- Road traffic accidents and psychotropic medication use in the Netherlands: a case–control studyBritish Journal of Clinical Pharmacology, 2011
- Defining and Measuring Functional Recovery from DepressionCNS Drugs, 2010
- Mirtazapine, a Sedating Antidepressant, and Improved Driving Safety in Patients With Major Depressive DisorderThe Journal of Clinical Psychiatry, 2009
- The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: A double‐blind crossover trialHuman Psychopharmacology: Clinical and Experimental, 2008
- Antidepressants and Driving AbilityThe Journal of Clinical Psychiatry, 2006
- Actual Driving Performance and Psychomotor Function in Healthy Subjects After Acute and Subchronic Treatment With Escitalopram, Mirtazapine, and PlaceboThe Journal of Clinical Psychiatry, 2005
- Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteersEuropean Neuropsychopharmacology, 1995